Open AccessSuccessful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir
Author(s) -
Oda Naohiro,
Miyoshi Keiji,
Morichika Daisuke,
Beika Yuka,
Taki Takahiro,
Mitani Reo,
Okada Toshiaki,
Takata Ichiro
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4459
Subject(s) - medicine , pembrolizumab , concomitant , methylprednisolone , adverse effect , lung cancer , immune system , cancer , oncology , immunotherapy , immunology
Abstract COVID‐19 in cancer patients on immunosuppressive agents for the treatment of immune‐related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID‐19, and further clinical trials are warranted.